淋巴瘤循环肿瘤DNA:精准医学时代

Avyakta Kallam, Jayanth Adusumalli, Kai Fu, James O. Armitage
{"title":"淋巴瘤循环肿瘤DNA:精准医学时代","authors":"Avyakta Kallam,&nbsp;Jayanth Adusumalli,&nbsp;Kai Fu,&nbsp;James O. Armitage","doi":"10.1002/acg2.81","DOIUrl":null,"url":null,"abstract":"<p>Non-Hodgkin's lymphomas are heterogeneous lymphoid malignancies, usually with an excellent prognosis. Aggressive B-cell lymphomas, such as diffuse large B-cell lymphomas, are treated with a curative intent with first-line therapy achieving a cure rate in about 70% of patients. Indolent lymphomas, such as follicular lymphoma (FL), are considered less curable, with the goal of treatment directed toward inducting deep remissions. With treatment strategies evolving more toward precision medicine, there is a need for better diagnostic, prognostic biomarkers. Circulating tumor DNA (ct-DNA) shed into the blood by tumor cells can be used as a marker for identification of tumor, assessment of tumor response, and to predict long-term outcomes. Recent studies have demonstrated the potential of these techniques as a prognostic tool. We review the clinical data supporting the role of ct-DNA in non-Hodgkin's lymphomas.</p>","PeriodicalId":72084,"journal":{"name":"Advances in cell and gene therapy","volume":"3 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/acg2.81","citationCount":"2","resultStr":"{\"title\":\"Circulating tumor DNA in lymphomas: Era of precision medicine\",\"authors\":\"Avyakta Kallam,&nbsp;Jayanth Adusumalli,&nbsp;Kai Fu,&nbsp;James O. Armitage\",\"doi\":\"10.1002/acg2.81\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Non-Hodgkin's lymphomas are heterogeneous lymphoid malignancies, usually with an excellent prognosis. Aggressive B-cell lymphomas, such as diffuse large B-cell lymphomas, are treated with a curative intent with first-line therapy achieving a cure rate in about 70% of patients. Indolent lymphomas, such as follicular lymphoma (FL), are considered less curable, with the goal of treatment directed toward inducting deep remissions. With treatment strategies evolving more toward precision medicine, there is a need for better diagnostic, prognostic biomarkers. Circulating tumor DNA (ct-DNA) shed into the blood by tumor cells can be used as a marker for identification of tumor, assessment of tumor response, and to predict long-term outcomes. Recent studies have demonstrated the potential of these techniques as a prognostic tool. We review the clinical data supporting the role of ct-DNA in non-Hodgkin's lymphomas.</p>\",\"PeriodicalId\":72084,\"journal\":{\"name\":\"Advances in cell and gene therapy\",\"volume\":\"3 3\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-02-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/acg2.81\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in cell and gene therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/acg2.81\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in cell and gene therapy","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/acg2.81","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

摘要

非霍奇金淋巴瘤是一种异质性淋巴样恶性肿瘤,通常预后良好。侵袭性b细胞淋巴瘤,如弥漫性大b细胞淋巴瘤,一线治疗的治愈率约为70%。惰性淋巴瘤,如滤泡性淋巴瘤(FL),被认为是难以治愈的,治疗的目标是诱导深度缓解。随着治疗策略向精准医学发展,需要更好的诊断和预后生物标志物。肿瘤细胞释放到血液中的循环肿瘤DNA (ct-DNA)可作为识别肿瘤、评估肿瘤反应和预测长期预后的标志物。最近的研究已经证明了这些技术作为预后工具的潜力。我们回顾了支持ct-DNA在非霍奇金淋巴瘤中的作用的临床数据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Circulating tumor DNA in lymphomas: Era of precision medicine

Non-Hodgkin's lymphomas are heterogeneous lymphoid malignancies, usually with an excellent prognosis. Aggressive B-cell lymphomas, such as diffuse large B-cell lymphomas, are treated with a curative intent with first-line therapy achieving a cure rate in about 70% of patients. Indolent lymphomas, such as follicular lymphoma (FL), are considered less curable, with the goal of treatment directed toward inducting deep remissions. With treatment strategies evolving more toward precision medicine, there is a need for better diagnostic, prognostic biomarkers. Circulating tumor DNA (ct-DNA) shed into the blood by tumor cells can be used as a marker for identification of tumor, assessment of tumor response, and to predict long-term outcomes. Recent studies have demonstrated the potential of these techniques as a prognostic tool. We review the clinical data supporting the role of ct-DNA in non-Hodgkin's lymphomas.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信